Supplementary Figure 1: DPP4i diminishes tumor volume and DPP enzymatic activity in Hepa1-6 and EMT6 subcutaneous tumors. | Nature Immunology

Supplementary Figure 1: DPP4i diminishes tumor volume and DPP enzymatic activity in Hepa1-6 and EMT6 subcutaneous tumors.

From: Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth

Supplementary Figure 1

(a, b) WT mice were fed with DPP4i or with Ctrl chow and subcutaneously injected with Hepa 1-6 (a) or EMT6 (b) cells. Tumors were collected at day 10 post-inoculation and tumor mass was determined. Bars represent median values (n = 17 (Ctrl, panel a), 18 (DPP4i, panel a) or 6 per group (b)). (c, d) Eight days after Hepa 1-6 (c) or EMT6 (d) tumor cell inoculation, tumors were collected and homogenates were prepared. DPP4 activity per tumor mass was determined and normalized to the amount of DPP4 protein (RLU, relative luminescence units). Bars represent median values (n = 4 per group (c), 6 (Ctrl, d) or 7 (DPP4i, d) mice). (e) Hepa 1-6 cells were cultured in the presence of 5 (C1), 0.05 (C2) or 0.005 (C3) μg/ml of DPP4i, or left untreated (∅). Cell confluence was measured over time using intra-incubator microscopy (mean ± SEM, n = 3 technical replicates). Each dot corresponds to one mouse. Data are representative of two independent experiments (b–e) or pooled from two (a) independent experiments. NS, not significant; *P < 0.05, ****P < 0.0001. Significance was determined using two-sided Mann–Whitney test (a–d). (Allergy 63, 1156–1163, 2008)

Back to article page